![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 27
Zeitschriftenartikel
Boukovala, Myrto; Modest, Dominik Paul; Ricard, Ingrid; Fischer von Weikersthal, Ludwig; Decker, Thomas; Vehling-Kaiser, Ursula; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Peveling Genannt Reddemann, C.; Graeven, Ullrich 
ORCID: https://orcid.org/0000-0001-6082-7710; Schuch, Gunter ORCID: https://orcid.org/0000-0001-7503-457X; Schwaner, Ingo ORCID: https://orcid.org/0000-0001-8865-7282; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Neumann, Jens; Jung, Andreas; Held, Swantje ORCID: https://orcid.org/0000-0002-1344-9056; Stintzing, Sebastian ORCID: https://orcid.org/0000-0002-3297-5801; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Michl, Marlies ORCID: https://orcid.org/0000-0002-4198-3627
(2024):
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
In: ESMO Open, Bd. 9, Nr. 5, 103374
[PDF, 725kB]
ORCID: https://orcid.org/0000-0001-6082-7710; Schuch, Gunter ORCID: https://orcid.org/0000-0001-7503-457X; Schwaner, Ingo ORCID: https://orcid.org/0000-0001-8865-7282; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Neumann, Jens; Jung, Andreas; Held, Swantje ORCID: https://orcid.org/0000-0002-1344-9056; Stintzing, Sebastian ORCID: https://orcid.org/0000-0002-3297-5801; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Michl, Marlies ORCID: https://orcid.org/0000-0002-4198-3627
(2024):
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
In: ESMO Open, Bd. 9, Nr. 5, 103374
[PDF, 725kB]
Alig, Annabel H. S.; Heinemann, Volker; Geissler, Michael; Fischer von Weikersthal, Ludwig; Decker, Thomas; Heinrich, Kathrin; Held, Swantje; Weiss, Lena; Moosmann, Nicolas; Stahler, Arndt; Jelas, Ivan; Kurreck, Annika; Einem, Jobst C. von; Reinacher-Schick, Anke C.; Tannapfel, Andrea; Giessen-Jung, Clemens; Stintzing, Sebastian und Modest, Dominik P. von
(2022):
Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy.
In: Cancers, Bd. 14, Nr. 3, 526
Kurreck, Annika; Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Graeven, Ullrich; Heinrich, Kathrin; Held, Swantje; Stahler, Arndt; Alig, Annabel Helga Sophie; Jelas, Ivan; Einem, Jobst C. von; Stintzing, Sebastian; Giessen-Jung, Clemens und Modest, Dominik P.
(2022):
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.
In: Frontiers in Oncology, Bd. 12, 751453
Modest, Dominik Paul; Karthaus, Meinolf; Fruehauf, Stefan; Graeven, Ullrich; Müller, Lothar; König, Alexander Otto; Fischer von Weikersthal, Ludwig; Caca, Karel; Kretzschmar, Albrecht; Goekkurt, Eray; Haas, Siegfried; Kurreck, Annika; Stahler, Arndt; Held, Swantje; Jarosch, Armin; Horst, David; Reinacher-Schick, Anke; Kasper, Stefan; Heinemann, Volker; Stintzing, Sebastian und Trarbach, Tanja
(2022):
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212).
In: Journal of Clinical Oncology, Bd. 40, Nr. 1: S. 72-82
Stahler, Arndt; Modest, Dominik P.; Fischer von Weikersthal, Ludwig; Kaiser, Florian; Decker, Thomas; Held, Swantje; Graeven, Ullrich; Schwaner, Ingo; Denzlinger, Claudio; Schenk, Michael; Kurreck, Annika; Heinrich, Kathrin; Giessen-Jung, Clemens; Neumann, Jens; Kirchner, Thomas; Jung, Andreas; Stintzing, Sebastian und Heinemann, Volker
(2022):
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
In: European Journal of Cancer, Bd. 173: S. 194-203
Hirt, Carsten; Hoster, Eva; Unterhalt, Michael; Haenel, Mathias; Prange-Krex, Gabriele; Forstpointner, Roswitha; Florschuetz, Axel; Graeven, Ullrich; Frickhofen, Norbert; Wulf, Gerald; Lengfelder, Eva; Lerchenmueller, Christian; Schlag, Rudolf; Dierlamm, Judith; Fischer von Weikersthal, Ludwig; Ahmed, Asima; Harich, Hanns-Detlev; Rosenwald, Andreas; Klapper, Wolfram; Dreyling, Martin; Hiddemann, Wolfgang und Herold, Michael
(2021):
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hamatologie und Onkologie and the German Low-Grade Lymphoma Study Group.
In: Hemasphere, Bd. 5, Nr. 7, e600
Heinrich, Kathrin; Modest, Dominik P.; Ricard, Ingrid; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Graeven, Ullrich; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Giessen-Jung, Clemens; Stahler, Arndt; Michl, Marlies; Held, Swantje; Jung, Andreas; Kirchner, Thomas; Stintzing, Sebastian und Heinemann, Volker
(2021):
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).
In: European Journal of Cancer, Bd. 147: S. 128-139
Hirt, Carsten; Hoster, Eva; Unterhalt, Michael; Hänel, Mathias; Prange-Krex, Gabriele; Forstpointner, Roswitha; Florschütz, Axel; Graeven, Ullrich; Frickhofen, Norbert; Wulf, Gerald; Lengfelder, Eva; Lerchenmüller, Christian; Schlag, Rudolf; Dierlamm, Judith; Fischer von Weikersthal, Ludwig; Ahmed, Asima; Harich, Hanns-Detlev; Rosenwald, Andreas; Klapper, Wolfram; Dreyling, Martin; Hiddemann, Wolfgang und Herold, Michael
(2021):
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients. A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group.
In: HemaSphere, Bd. 5, Nr. 7, e600
Stahler, Arndt; Stintzing, Sebastian; Modest, Dominik P.; Ricard, Ingrid; Giessen-Jung, Clemens; Kapaun, Christine; Ivanova, Boryana; Kaiser, Florian; Fischer von Weikersthal, Ludwig; Moosmann, Nicolas; Schalhorn, Andreas; Stauch, Martina; Kiani, Alexander; Held, Swantje; Decker, Thomas; Moehler, Markus; Neumann, Jens; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker
(2020):
Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials.
In: Clinical Cancer Research, Bd. 26, Nr. 24: S. 6559-6567
Schulz, Christoph; Heinemann, Volker; Heinrich, Kathrin; Haas, Michael; Holch, Julian W.; Fraccaroli, Alessia; Held, Swantje; Einem, Jobst C.von; Modest, Dominik P.; Fischer von Weikersthal, Ludwig; Kullmann, Frank; Moehler, Markus; Scheithauer, Werner; Jung, Andreas und Stintzing, Sebastian
(2020):
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
In: Anti-Cancer Drugs, Bd. 31, Nr. 8: S. 856-865
Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Kaiser, Florian; Al-Batran, Salah-Edin; Heintges, Tobias; Lerchenmüller, Christoph; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Moehler, Markus; Scheithauer, Werner; Held, Swantje; Miller-Phillips, Lisa; Modest, Dominik Paul; Jung, Andreas; Kirchner, Thomas und Stintzing, Sebastian
(2020):
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
In: British Journal of Cancer, Bd. 124, Nr. 3: S. 587-594
Stahler, Arndt; Stintzing, Sebastian; Einem, Jobst C. von; Westphalen, Christoph B.; Heinrich, Kathrin; Kraemer, Nicole; Michl, Marlies; Modest, Dominik P.; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Moehler, Markus; Kaiser, Florian; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker
(2020):
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.
In: European Journal of Cancer, Bd. 137: S. 250-259
Kurreck, Annika; Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Graeven, Ullrich; Schwaner, Ingo; Stahler, Arndt; Heinrich, Kathrin; Jung, Andreas; Held, Swantje; von Einem, Jobst C.; Stintzing, Sebastian; Giessen-Jung, Clemens und Modest, Dominik P.
(2020):
Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).
In: European Journal of Cancer, Bd. 137: S. 81-92
Al-Batran, Salah-Eddin; Homann, Nils; Pauligk, Claudia; Götze, Thorsten O.; Meiler, Johannes; Kasper, Stefan; Kopp, Hans-Georg; Mayer, Frank; Haag, Georg Martin; Luley, Kim; Lindig, Udo; Schmiegel, Wolff; Pohl, Michael; Stoehlmacher, Jan; Folprecht, Gunnar; Probst, Stephan; Prasnikar, Nicole; Fischbach, Wolfgang; Mahlberg, Rolf; Trojan, Jörg; Königsmann, Michael; Martens, Uwe M.; Thuss-Patience, Peter; Egger, Matthias; Block, Andreas; Heinemann, Volker; Illerhaus, Gerald; Moehler, Markus; Schenk, Michael; Kullmann, Frank; Behringer, Dirk M.; Heike, Michael; Pink, Daniel; Teschendorf, Christian; Loehr, Carmen; Bernhard, Helga; Schuch, Gunter; Rethwisch, Volker; Fischer von Weikersthal, Ludwig; Hartmann, Jörg T.; Kneba, Michael; Daum, Severin; Schulmann, Karsten; Weniger, Jörg; Belle, Sebastian; Gaiser, Timo; Oduncu, Fuat S.; Guentner, Martina; Hozaeel, Wael; Reichart, Alexander; Jaeger, Elke; Kraus, Thomas; Moenig, Stefan; Bechstein, Wolf O.; Schuler, Martin; Schmalenberg, Harald und Hofheinz, Ralf D.
(2019):
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
In: Lancet, Bd. 393, Nr. 10184: S. 1948-1957
Modest, Dominik Paul; Fischer von Weikersthal, Ludwig; Decker, Thomas; Vehling-Kaiser, Ursula; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Reddemann, Christina Peveling Genannt; Graeven, Ullrich; Schuch, Gunter; Schwaner, Ingo; Stahler, Arndt; Jung, Andreas; Kirchner, Thomas; Held, Swantje; Stintzing, Sebastian; Giessen-Jung, Clemens und Heinemann, Volker
(2019):
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled StudyXELAVIRI (AIO KRK0110).
In: Journal of Clinical Oncology, Bd. 37, Nr. 1
Cramer, Paula; Tresckow, Julia von; Bahlo, Jasmin; Robrecht, Sandra; Langerbeins, Petra; Al-Sawaf, Othman; Engelke, Anja; Fink, Anna-Maria; Fischer, Kirsten; Tausch, Eugen; Seiler, Till; Fischer von Weikersthal, Ludwig; Hebart, Holger; Kreuzer, Karl-Anton; Boettcher, Sebastian; Ritgen, Matthias; Kneba, Michael; Wendtner, Clemens-Martin; Stilgenbauer, Stephan; Eichhorst, Barbara und Hallek, Michael
(2018):
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
In: Lancet Oncology, Bd. 19, Nr. 9: S. 1215-1228
Holch, J. W.; Ricard, I.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Jelas, I.; Modest, D. P.; Westphalen, C. B.; Einem, J. C. von; Michl, M. und Heinemann, V.
(2018):
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
In: European Journal of Cancer, Bd. 106: S. 115-125
Holch, Julian W.; Ricard, Ingrid; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Scholz, Michael; Müller, Sebastian; Link, Hartmut; Rost, Andreas; Höffkes, Heinz-Gert; Moehler, Markus; Lindig, Reinhard Udo; Miller-Phillips, Lisa; Kirchner, Thomas; Jung, Andreas; Einem, Jobst C. von; Modest, Dominik Paul und Heinemann, Volker
(2018):
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
In: International Journal of Cancer, Bd. 142, Nr. 5: S. 1047-1055
Modest, Dominik P.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Scheithauer, Werner; Kirchner, Thomas; Jung, Andreas; Stauch, Martina; Einem, Jobst Christian von; Möhler, Markus; Held, Swantje und Heinemann, Volker
(2017):
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
In: International Journal of Cancer, Bd. 140, Nr. 8: S. 1918-1925
Stahler, Arndt; Heinemann, Volker; Neumann, Jens; Crispin, Alexander; Schalhorn, Andreas; Stintzing, Sebastian; Giessen-Jung, Clemens; Fischer von Weikersthal, Ludwig; Vehling-Kaiser, Ursula; Stauch, Martina; Quietzsch, Detlef; Holch, Julian W.; Kruger, Stephan; Haas, Michael; Michl, Marlies; Einem, Jobst von; Kirchner, Thomas; Jung, Andreas und Modest, Dominik P.
(2017):
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
In: Anti-cancer drugs, Bd. 28, Nr. 7: S. 717-722
[PDF, 422kB]
Stintzing, Sebastian; Modest, Dominik P.; Rossius, Lisa; Lerch, Markus M.; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Giessen-Jung, Clemens; Moehler, Markus; Jagenburg, Andreas; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker
(2016):
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
In: Lancet Oncology, Bd. 17, Nr. 10: S. 1426-1434
Modest, Dominik Paul; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Sobrero, Alberto F.; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Seipelt, Gernot; Lerchenmüller, Christian A.; Kahl, Christoph; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Moehler, Markus H.; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2016):
Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab).
In: Journal of Clinical Oncology, Bd. 34, Nr. 4
Stintzing, Sebastian; Modest, Dominik Paul; Jung, Andreas; Kirchner, Thomas; Schäfer, Reinhold; Sers, Christine; Hildebrandt, Bert; Daum, Severin; Folprecht, Gunnar; Schuler, Martin H.; Kasper, Stefan; Trojan, Jorg; Jaeger, Dirk; Schulze-Bergkamen, Henning; Fischer von Weikersthal, Ludwig; Schalhorn, Alexander und Heinemann, Volker
(2016):
Differences in gene-expression in mCRC tissue samples with regard to tumor location and used chemotherapeutic substances: Data of the FIRE-1 study.
In: Journal of Clinical Oncology, Bd. 34, Nr. 4
Modest, Dominik P.; Schulz, Christoph; Fischer von Weikersthal, Ludwig; Quietzsch, Detlef; Einem, J. C. von; Schalhorn, Andreas; Vehling-Kaiser, Ursula; Laubender, Rüdiger P.; Giessen, Clemens; Stintzing, Sebastian und Heinemann, Volker
(2014):
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
In: Anticancer Drugs, Bd. 25, Nr. 2: S. 212-218
[PDF, 442kB]
Ormanns, Steffen; Siveke, Jens T.; Heinemann, Volker; Haas, Michael; Sipos, Bence; Schlitter, Anna Melissa; Esposito, Irene; Jung, Andreas; Laubender, Rüdiger P.; Kruger, Stephan; Vehling-Kaiser, Ursula; Winkelmann, Cornelia; Fischer von Weikersthal, Ludwig; Clemens, Michael R.; Gauler, Thomas C.; Märten, Angela; Geissler, Michael; Greten, Tim F.; Kirchner, Thomas und Boeck, Stefan
(2014):
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104.
In: BMC Cancer
14:624
[PDF, 408kB]
Heinemann, Volker; Vehling-Kaiser, Ursula; Waldschmidt, Dirk; Kettner, Erika; Märten, Angela; Winkelmann, Cornelia; Klein, Stefan; Kojouharoff, Georgi; Gauler, Thomas C.; Fischer von Weikersthal, Ludwig; Clemens, Michael R.; Geissler, Michael; Greten, Tim F.; Hegewisch-Becker, Susanna; Rubanov, Oleg; Baake, Gerold; Höhler, Thomas; Ko, Yon D.; Jung, Andreas; Neugebauer, Sascha und Böck, Stefan
(Mai 2013):
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the `Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
In: Gut, Bd. 62, Nr. 5: S. 751-759
[PDF, 468kB]
Giessen, Clemens; Fischer von Weikersthal, Ludwig; Hinke, Axel; Stintzing, Sebastian; Kullmann, Frank; Vehling-Kaiser, Ursula; Mayerle, Julia; Bangerter, Markus; Denzlinger, Claudio; Sieber, Markus; Teschendorf, Christian; Freiberg-Richter, Jens; Schulz, Christoph; Modest, Dominik Paul; Moosmann, Nicolas; Aubele, Philipp und Heinemann, Volker
(2011):
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial.
In: BMC Cancer
11:367
[PDF, 533kB]